logo

GMAB

GenmabยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

GMAB fundamentals

Genmab (GMAB) released its earnings on Nov 6, 2025: revenue was 1.02B (YoY -81.59%), beat estimates; EPS was 0.65 (YoY -96.74%), beat estimates.
Revenue / YoY
1.02B
-81.59%
EPS / YoY
0.65
-96.74%
Report date
Nov 6, 2025
GMAB Earnings Call Summary for Q3,2025
  • Revenue Growth: 21% YoY total revenue, 26% recurring revenue growth, EPKINLY up 64%, TIVDAK launched in Germany.
  • Pipeline Momentum: Rina-S Phase III in endometrial cancer (50% ORR), EPKINLY awaiting U.S. approval, Merus acquisition adds petosemtamab (2027 launch).
  • Financial Strength: Operating profit +52%, $3.4B cash, 2026 EBIT significant, 2027 EBITDA growth.
EPS
Revenue

Revenue & Expenses

GMAB has released its 2025 Q3 earnings report, with revenue of 1.02B, reflecting a YoY change of 25.25%, and net profit of 401.00M, showing a YoY change of 115.59%. The Sankey diagram below clearly presents GMAB's revenue sources and cost distribution.

Key Indicators

Genmab (GMAB) key financial stats and ratios, covering profitability, financial health, and leverage.
Genmab (GMAB)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Genmab (GMAB)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Genmab (GMAB)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Genmab (GMAB) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Genmab (GMAB) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield